// App-Quantinova.ai

: Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.

Researchers

Presenter

  • Disharee Nath

Principal Investigators

  • Claudia Mondragon

  • Dawn Post

  • Ming Chen

  • Anita Hryniewicz-Jankowska

  • Tiffany Caza

  • Julie White

  • Vladimir Kuznetsov

  • Heidi Hehnly

  • Rakesh Khanna

  • Stephanie Gleicher

  • Tamara Jamaspishvili

  • David Monty Berman

  • Fan Zhang

  • Sonia H.Y. Kung

  • Ladan Fazli

  • Gennady Bratslavsky

  • Pier Paolo Pandolfi

  • Leszek Kotula

Medical Centers

  • Upstate Medical University, Syracuse, NY

  • Duke University College of Medicine, Durham, NC

  • Boulder BioPATH, Inc., Boulder, CO

  • Syracuse University, Syracuse, NY

  • Queen's University, Kingston, ON, CA

  • Johns Hopkins University, Baltimore, MD

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

  • Upstate Medical University, Syracuse, NY

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Teratoma

  • Solid malignancies

Biomarkers

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved